Cytokinetics INC 8-K filings

Cytokinetics has filed a complaint against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment of non-infringement and invalidity of a specific patent.

Cytokinetics, Inc. reported on its 2026 Annual Meeting of Stockholders, where directors were elected, an employee stock purchase plan was amended, and the independent auditor was ratified.

Cytokinetics, Inc. has finalized a public offering of common stock, raising approximately $760.2 million to bolster its financial position.

Cytokinetics, Inc. provided a corporate presentation detailing its approved products, pipeline advancements, and financial position, highlighting progress in cardiovascular and neuromuscular diseases.

Cytokinetics announced strong first quarter 2026 financial results, driven by the successful U.S. launch of MYQORZO and positive clinical trial updates.

Cytokinetics announced its Q4 and full-year 2025 financial results, highlighting the successful U.S., China, and Europe approvals and launch of MYQORZO for oHCM, alongside 2026 financial guidance.

The European Commission has granted approval for Cytokinetics' MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients.

Cytokinetics announced FDA approval for MYQORZO (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in adults.

Cytokinetics announced a positive opinion from the European Medicines Agency's CHMP for MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy.

Cytokinetics, Incorporated announced the appointment of Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025.

Cytokinetics reported third quarter 2025 financial results, highlighted by progress towards the December 26, 2025 PDUFA date for aficamten and a strengthened cash position of $1.25 billion.

Cytokinetics successfully issued $750 million in 1.75% Convertible Senior Notes due 2031, refinancing a portion of its 2027 notes and bolstering funds for its pipeline and aficamten's potential commercial launch.

Cytokinetics provided regulatory updates for aficamten in oHCM, including a Late Cycle Meeting with the FDA and EMA responses, while also announcing plans to draw $100 million in Tranche 5 term loans.

Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting improved cardiac structure and function and a low incidence of atrial fibrillation.

Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting improved cardiac structure and function and a low incidence of atrial fibrillation.

Cytokinetics announced positive primary results from its MAPLE-HCM Phase 3 trial, demonstrating aficamten's superiority over metoprolol in treating obstructive hypertrophic cardiomyopathy.

Cytokinetics, Incorporated announced the appointment of James M. Daly as an independent Class III member to its Board of Directors and Compliance Committee.

Cytokinetics reports Q2 2025 financial results, highlighting progress in aficamten regulatory reviews and clinical trials, alongside increased revenues and ongoing commercial readiness.

Cytokinetics' annual meeting saw stockholders approve key proposals, including an increase in authorized shares and the election of Class III directors.

Cytokinetics announced its Q1 2025 financial results, highlighted by ~$1.1 billion in cash and investments, and provided a business update including the extension of the aficamten PDUFA date to December 26, 2025.

The FDA has extended the PDUFA action date for Cytokinetics' aficamten NDA for obstructive hypertrophic cardiomyopathy (oHCM) to December 26, 2025, due to the need for a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS).

Cytokinetics announces completion of midcycle review with the FDA for aficamten and provides updates on the NDA process.

Cytokinetics announces Q4 2024 financial results, highlights progress in aficamten's regulatory approvals, and provides 2025 financial guidance.

Cytokinetics appoints Robert E. Landry to its Board of Directors, effective February 10, 2025, also joining the Audit Committee.

Cytokinetics has announced the departure of its Chief Accounting Officer, Robert Wong, effective December 31, 2024, with Chief Financial Officer Sung Lee assuming the additional role of principal accounting officer.

Cytokinetics has granted Bayer an exclusive license to develop and commercialize its heart drug, aficamten, in Japan, securing an upfront payment and potential future milestones.

Santo J. Costa resigned from Cytokinetics' Board of Directors effective November 1, 2024, for personal reasons.

Cytokinetics has appointed Brett Pletcher as its new Executive Vice President, Chief Legal Officer, effective August 19, 2024.

Cytokinetics announced its second quarter 2024 financial results, highlighted by significant clinical advancements and a substantial increase in cash reserves to $1.4 billion.

Cytokinetics has successfully raised approximately $75 million through the full exercise of an underwriter's option to purchase additional shares of common stock.